Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + methotrexate + leucovorin
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination chemotherapy regimen consisting of cyclophosphamide, doxorubicin, methotrexate, and leucovorin. This combination is often used as part of larger regimens for treating non-Hodgkin lymphoma, particularly large-cell lymphoma. Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, while leucovorin (folinic acid) is used as a "rescue" agent to reduce methotrexate toxicity. Cyclophosphamide is an alkylating agent that cross-links DNA strands, and doxorubicin is an anthracycline antibiotic that damages DNA by intercalation.
- Other names
- m-BACOD (when combined with bleomycin, vincristine, and dexamethasone)
02
Targets
DHFR (Dihydrofolate reductase)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + methotrexate + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + methotrexate + leucovorin.